Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
29 Sep 2016 FDA Modifies the Dosage Regimen for Currently Approved Indications for Nivolumab Genitourinary cancers - Melanoma - Lung and other thoracic tumours - Anticancer agents & Biologic therapy
28 Sep 2016 EU-US collaboration to boost medicine development for rare diseases Bioethics, legal and economic issues
27 Sep 2016 NICE Releases a Quality Standard in Skin Cancer Melanoma
22 Sep 2016 EMA Recommends Granting a Marketing Authorisation for Edotreotide Imaging - Endocrine cancers
21 Sep 2016 EMA Recommends Granting a Conditional Marketing Authorisation for Ixazomib Haematologic malignancies - Anticancer agents & Biologic therapy
20 Sep 2016 EMA Recommends Granting a Conditional Marketing Authorisation for Olaratumab Sarcomas - Anticancer agents & Biologic therapy
19 Sep 2016 Press Release: Launch of First eUpdate Integrating Breakthroughs in ESMO Clinical Practice Guidelines
19 Sep 2016 EMA Recommends Granting a Marketing Authorisation for Palbociclib Breast cancer - Anticancer agents & Biologic therapy
16 Sep 2016 Start-Up of Human Cancer Models Initiative Translational research
15 Sep 2016 Niraparib Receives FDA Fast Track Designation for the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Gynaecologic malignancies - Anticancer agents & Biologic therapy
08 Sep 2016 CDK4/6 Inhibitor LEE011 (Ribociclib) Receives FDA Breakthrough Therapy Designation Breast cancer - Anticancer agents & Biologic therapy
07 Sep 2016 Potential Risk of Hepatitis B Reactivation After Treatment With BCR-ABL Tyrosine Kinase Inhibitors Anticancer agents & Biologic therapy
06 Sep 2016 Press Release: ESMO Rewards Outstanding Oncologists
06 Sep 2016 Annals of Oncology Press Release: Deaths from Ovarian Cancer Decline Worldwide Due to Oral Contraceptive Use Gynaecologic malignancies
05 Sep 2016 Completion of Rolling Submission of New Drug Application for Brigatinib to the US FDA Personalised medicine - Lung and other thoracic tumours - Anticancer agents & Biologic therapy